<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136994</url>
  </required_header>
  <id_info>
    <org_study_id>A1281045</org_study_id>
    <nct_id>NCT00136994</nct_id>
  </id_info>
  <brief_title>IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)</brief_title>
  <official_title>An Open Trial to Evaluate the Efficacy and Tolerability of Ziprasidone IM and Oral in Patients With Psychosis and Acute Agitation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer's Upjohn has merged with Mylan to form Viatris Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      To evaluate efficacy and tolerability of Ziprasidone IM and oral in agitated patients with&#xD;
      acute exacerbation of schizophrenia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate efficacy and tolerability of Ziprasidone IM and oral in agitated patients with acute exacerbation of schizophrenia</measure>
  </primary_outcome>
  <enrollment>160</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Psychiatric:&#xD;
&#xD;
          -  Diagnosis of schizophrenia using DSM-IV (295.xx).&#xD;
&#xD;
          -  Patients entering hospital (or inpatients transferring to higher-dependency unit)&#xD;
             within the previous seven days because of acute exacerbation of psychotic symptoms.&#xD;
&#xD;
          -  PANSS &gt; 80 (score Â³ 3 on at least three of the following PANSS agitation items:&#xD;
             anxiety , tension, hostility, excitement).&#xD;
&#xD;
          -  CGI-S Â³ 4. - Indication, based on intensity/severity of psychotic symptoms, on IM&#xD;
             therapy.&#xD;
&#xD;
          -  General:&#xD;
&#xD;
          -  Male or Female patients aged 18-60 years at screening.&#xD;
&#xD;
          -  Written informed consent to participation.&#xD;
&#xD;
          -  Female patients of at risk of pregnancy must avoid to remain pregnant; an adequate&#xD;
             method of contraception can be initiated or continued.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric:&#xD;
&#xD;
          -  Patients at immediate risk of committing harm to self or others&#xD;
&#xD;
          -  Concurrent treatment with other antipsychotic agents after baseline&#xD;
&#xD;
          -  Patients receiving depot antipsychotic medication within 21 days of screening&#xD;
&#xD;
          -  Treatment with antidepressants or mood stabilizers (such as lithium, carbamazepine,&#xD;
             valproic acid or verapamil) within two weeks of screening&#xD;
&#xD;
          -  Diagnosis of substance abuse using DSM-IV criteria within previous 12 months&#xD;
&#xD;
          -  Positive urine drug screen at screening for amphetamine, cocaine or opioids&#xD;
&#xD;
          -  Alcohol and/or any other drug abuse at screening&#xD;
&#xD;
          -  Patients who have received clozapine within 3 months prior to screening due to&#xD;
             intolerance to other antipsychotics or patients who have received clozapine in the&#xD;
             past two years for refractoriness to treatment&#xD;
&#xD;
          -  Treatment with any investigational agent within the previous six months&#xD;
&#xD;
          -  Previous treatment with ziprasidone&#xD;
&#xD;
          -  Organic mental disease, including mental retardation&#xD;
&#xD;
          -  History of psychosurgery&#xD;
&#xD;
          -  General:&#xD;
&#xD;
          -  Patients with a history of clinically significant and/or currently relevant&#xD;
             hematological, renal (including single kidney), hepatic, gastrointestinal, endocrine&#xD;
             (except for current adequately treated hypo- or hyperthyroidism), pulmonary (excluding&#xD;
             chronic bronchitis, mild emphysema or chronic obstructive pulmonary disease),&#xD;
             dermatological, oncological, or neurological disease, excluding tardive dyskinesia but&#xD;
             including all forms of epilepsy (febrile convulsions in childhood acceptable). The&#xD;
             only patients with known prior malignant disease who are eligible are those with cured&#xD;
             prior skin cancer (excluding melanoma). Controlled Type II diabetes (glucose &lt; 180&#xD;
             mg/100 ml at screening and baseline with dietary or oral hypoglycemic treatment) will&#xD;
             not be considered a significant medical illness and would not exclude a subject from&#xD;
             the study - Patients with a history of significant cardiovascular disease or&#xD;
             significant concurrent cardiovascular disease, including a history of uncontrolled&#xD;
             hypertension (supine diastolic pressure &gt;95 mm Hg and/or supine systolic pressure &gt;&#xD;
             170 mm Hg with or without treatment)&#xD;
&#xD;
          -  Clinically significant ECG abnormality&#xD;
&#xD;
          -  Patient with QTc Â³ 450 msec - Concomitant treatment with medications that prolong QT&#xD;
             interval&#xD;
&#xD;
          -  Patients with serum K+ or Mg++ outside the normal range&#xD;
&#xD;
          -  Confirmed clinically significant laboratory values.&#xD;
&#xD;
          -  Known serological evidence of HIV, or acute or chronic hepatitis (with transaminase&#xD;
             levels higher than three times the normal limits)&#xD;
&#xD;
          -  Patients who intend to donate blood or blood products during the 4 weeks prior to the&#xD;
             study, during the study or in the 30 days after the study ends&#xD;
&#xD;
          -  Patients unable or unlikely to follow the study protocol&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients with a history of neuroleptic malignant syndrome developing from the&#xD;
             administration of antipsychotic compounds&#xD;
&#xD;
          -  Known hypersensitivity to ziprasidone or lactose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Savigliano</city>
        <state>Cuneo</state>
        <zip>12038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Campi Bisenzio</city>
        <state>Firenze</state>
        <zip>50013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sora</city>
        <state>Frosinone</state>
        <zip>3039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>S. Arsenio</city>
        <state>Salerno</state>
        <zip>84037</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bologna</city>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Caserta</city>
        <zip>81100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chiari (BS)</city>
        <zip>25032</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fidenza(pr)</city>
        <zip>43036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Foggia</city>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Genova-sestri</city>
        <zip>16154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moncalieri(to)</city>
        <zip>10024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Napoli</city>
        <zip>80136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Noto</city>
        <zip>96017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orbassano (to)</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palermo</city>
        <zip>90145</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Perugia</city>
        <zip>06100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Senigallia (AN)</city>
        <zip>60019</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torino</city>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torrette DI Ancona (AN)</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Verona</city>
        <zip>37063</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Viareggio</city>
        <zip>55049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

